Esperion Therapeutics (ESPR) Non-Current Assets (2012 - 2026)

Esperion Therapeutics' Non-Current Assets history runs 15 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• Quarterly Non-Current Assets fell 41.57% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (down 41.92% YoY) and the FY2025 annual result came in at $3.3 million, down 43.05% from the prior year.
• Non-Current Assets was $3.1 million for Q1 2026 at Esperion Therapeutics, down from $3.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $52.0 million in Q1 2022 and bottomed at $1.2 million in Q1 2023.
• A 5-year average of $12.6 million and a median of $4.7 million in 2023 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets jumped 874.13% — and 2023, when it plunged 97.67%.
• Esperion Therapeutics' Non-Current Assets stood at $1.3 million in 2022, then jumped by 276.67% to $4.7 million in 2023, then grew by 23.08% to $5.8 million in 2024, then slumped by 43.05% to $3.3 million in 2025, then fell by 7.48% to $3.1 million in 2026.
• Business Quant data shows ESPR's Non-Current Assets at $3.1 million in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.